Patient characteristics and baseline parameters on Study Day 1 and Study Day 2 including last haematocrit, actual dose of caffeine, mode of respiratory support, supplemental oxygen and number of patients which are already set on elevated SpO2 target range for clinical reasons
| Patient characteristics | n (%) | Median | Range | |||
|---|---|---|---|---|---|---|
| Number of patients | 16 | |||||
| Gestational age (weeks) | 25.9 | 22.6–30.4 | ||||
| Birth weight (g) | 537 | 312–1150 | ||||
| Antenatal corticoids (complete course) | 10 (63) | |||||
| Mild BPD (28 days O2) | 15 (94) | |||||
| Moderate or severe BPD (O2 at 36 weeks) | 6 (38) | |||||
| Intracranial haemorrhage | 1 (6) | |||||
| Study Day | Study Day 1 | Study Day 2 | ||||
| n (%) | Median | Range | n (%) | Median | Range | |
| Age (days) | 30.5 | 7–52 | 34.5 | 8–58 | ||
| Weight (g) | 812 | 605–1336 | 925 | 605–1365 | ||
| Caffeine (mg/kg/day) | 6.0 | 5.0–10.0 | 7.0 | 5.0–10.0 | ||
| Haematocrit (%) | 44.5 | 31–53 | 41.0 | 29–55 | ||
| Respiratory support | ||||||
| CPAP | 8 (50) | 8 (50) | ||||
| NIPPV | 5 (31) | 6 (38) | ||||
| Invasive ventilation | 3 (19) | 2 (12) | ||||
| Supplemental oxygen (%) | 27 | 21–50 | 26 | 21–43 | ||
| Elevated SpO2 target range (85–96%) | 5 (31) | 5 (31) | ||||
BPD, bronchopulmonary dysplasia; CPAP, continuous positive airway pressure; NIPPV, non-invasive positive pressure ventilation; SpO2, pulsoximetric oxygen saturation.